Emergent BioSolutions Inc. EBS, -13.40% said Friday that its experimental COVID-19 treatment did not demonstrate a clinical benefit in a late-stage clinical trial. The study was testing Emergent's immunoglobulin candidate with the standard of care, which uses Gilead Sciences Inc.'s GILD, +2.80% Veklury, in hospitalized patients with COVID-19 symptoms. "Emergent will continue to explore COVID-HIG as a treatment in ongoing clinical trials," Dr. Laura Saward, the head of the company's therapeutics business unit, said in a news release. The trial had received funding from the federal government. Emergent was in the news this week after Johnson & Johnson JNJ, -0.92% confirmed that some of its COVID-19 vaccines manufactured at an Emergent plant did not meet "quality standards." Emergent is the U.S. manufacturing partner to J&J for its coronavirus vaccines. Shares of Emergent have gained 71.0% over the past year, while S&P 500 SPX, +1.18% is up 53.7%.
https://www.marketwatch.com/story/emergent-says-experimental-covid-19-treatment-failed-in-phase-3-trial-2021-04-02
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.